

Cadila Healthcare Limited

Registered Office : Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015.

Tel. No. (+91-79) 2686 8100 Fax No. : (+91-79) 2686 2365/66 Website : www.zyduscadila.com Unaudited [Provisional] Consolidated Financial Results for the Quarter ended September 30, 2009.

				Rupees in La	acs [except for	share data]	
		Particulars	3 Months Corresponding 6 Months Corresponding				
Sr. No.			Period ended on	3 Months Period ended	Period ended on	6 Months Period ended	Previous Accounting
			30, 2009 [Unaudited]	30, 2008 [Unaudited]	30, 2009 [Unaudited]	30, 2008 [Unaudited]	March 31, 2009 [Audited]
1		Sales & Income from operations :	[Unauuiteu]	Tonaudited	[Unaudited]	Tonaudited	2009 Audited
1	А	Gross Sales	92,500	75,860	181,459	145,638	291,711
	В	Less : Excise Duty	1,242	2,075	2,170	3,280	5,471
	C	Net Sales	91,258	73,785	179,289	142,358	
	D	Other Income from Operations	3,320	308	5,643	3,141	6,509
	E	Total sales and other income from operations	94,578	74,093	184,932	145,499	
2	-	Expenditure :	54,570	71,055	104,552	115,155	252,715
	А	Increase [-] / Decrease [+] in stock in trade & work in progress	(1,654)	(6,094)	(4,273)	(3,742)	(4,607)
	В	Consumption of materials	22,845	15,195	44,910	31,787	66,946
	C	Purchase of traded goods	9,010	14,166	17,842	18,990	33,320
	D	Employees cost	11,120	9,260	21,366	18,105	35,208
	E	Depreciation & Amortisation	3,112	2,590	6,074	5,048	11,182
	F	-			-		-
		Other Expenditure	32,692	26,316	64,149	48,940	101,304
2	G	Total Expenditure	77,125	61,433	150,068	119,128	243,353
3		Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2]	17,453	12,660	34,864	26,371	49,396
4		Other Income	411	272	833	434	2,036
5		Profit before Interest & Exceptional Items [3 + 4]	17,864	12,932	35,697	26,805	51,432
6	A	Interest & financial charges	2,055	1,259	4,349	2,875	9,778
	В	Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans	253	1,135	394	2,452	2,270
_	С	Total Financial cost	2,308	2,394	4,743	5,327	12,048
7		Profit after Interest but before Exceptional Items [5 - 6]	15,556	10,538	30,954	21,478	39,384
8		Exceptional Items	(258)	(182)	(350)	(182)	(2,408)
9		Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8]	15,298	10,356	30,604	21,296	36,976
10		Tax expense	1,756	1,008	4,180	2,241	6,658
11		Net Profit [+] / Loss [-] from Ordinary Activities after tax [9 -10]	13,542	9,348	26,424	19,055	30,318
12		Extraordinary items [net of tax expense]	0	0	0	0	0
13		Net Profit [+] / Loss [-] for the period [11 - 12]	13,542	9,348	26,424	19,055	30,318
14		Adjustments on consolidation	(350)	140	(753)	(600)	(10)
15		Net Profit [+] / Loss [-] for the period [13 + 14]	13,192	9,488	25,671	18,455	30,308
16		Paid-up equity share capital [Face Value Rs. 5 /-]	6,824	6,280	6,824	6,280	6,824
17		Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year					116,700
18		Earnings Per Share [EPS] [For the period - not Annualised]:					
	Α	Basic and diluted EPS before Extraordinary items [Rs.]	9.66		18.81	13.52*	22.20
	В	Basic and diluted EPS after Extraordinary items [Rs.]	9.66	6.95*	18.81	13.52*	22.20
19		Public shareholding :					
		- Number of shares	34,406,982	35,150,458	34,406,982	35,150,458	34,629,818
		- Percentage of Shareholding	25.21%	27.98%	25.21%	27.98%	25.37%
20		Promoters and Promoter group Shareholding :					
	А	Pledged / Encumbered :					
		- Number of Shares	Nil	l Nil	Nil	Nil	Nil
		- Percentage of shares [as a % of the total shareholding of promoters and promoter group]	N.A.	N.A.	N.A.	N.A.	N.A.
		- Percentage of shares [as a % of the total share capital of the company]	N.A.	N.A.	N.A.	N.A.	N.A.
	В	Non-encumbered :					
			1				
		- Number of Shares	#######	90,463,250	102,092,031	90,463,250	101,869,195
		 Number of Shares Percentage of shares [as a % of the total shareholding of promoters and promoter group] 	####### 100.00%	90,463,250 100.00%			

Notes :

[1] Pursuant to the amendments to Clause 41 of the Listing Agreement, the company has opted to publish only the consolidated results of the company. Investors can view the standalone results of the company on the company's website : www.zyduscadila.com and/or on the websites of BSE [www.bseindia.com] and/or NSE [www.nseindia.com].

[2] The above results for the quarter / half year ended on September 30, 2009 were reviewed by the Audit Committee on October 26, 2009 and then approved by the Board of Directors at their meeting held on October 27, 2009 and the Statutory Auditors of the company have carried out limited review of the financial results of the Company for the quarter / half year ended September 30, 2009.

[3]* Earning per share in item 18 A & B for the three / six months period ended on September 30, 2008 is calculated taking into account the allotment of additional shares issued by the company pursuant to composite scheme of arrangement, to make the figures comparable.

[4] The status of investor complaints :

Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 28, pending at the end of the quarter - Ni

[5] The Company has one segment of activity viz. " Pharmaceuticals ".

By Order of the Board, For Cadila Healthcare Limited,

Pankaj R. Patel Chairman & Managing Director

Ahmedabad, October 27, 2009.